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The following six articles consider various novel approaches to 
tolerance induction. Becker et al. (2012) argue that as we gain a 
better understanding of the mechanisms by which Treg are induced 
we should reconsider the clinical use of monoclonal antibodies 
that target CD4, as these are proving to be particularly effective in 
a whole range of rodent models of transplantation and autoim-
munity. Hamad et al. (2012) suggest that the side effects that so far 
have limited translation of CD3 or CD20 antibody treatments in 
Type 1 Diabetes to the clinic (i.e., cytokine release, immunosup-
pression and EBV proliferation) could be avoided by targeting the 
FasL molecule, based on the resistance of mice that carry mutations 
in the Fas pathway of apoptosis to this autoimmune disease. In a 
different vein, Hirayama et al. (2012) discuss how the naturally 
acquired tolerance to non-inherited maternal antigens (NIMA) due 
to reciprocal microchimerism between the mother and fetus during 
pregnancy may be exploited to limit the risk of graft versus host 
disease in the choice of donors for bone marrow transplantation. 
Staying in the arena of hematopoietic transplantation, Carvalho 
et al. (2012) tackle the question of fungal infections and how tolero-
genic process may be required to limit the pathology caused by 
such infections in transplant recipients and how the interplay of 
anti-fungal and anti-allo responses may impact on the balance of 
effector cells and Treg generated. Andreev et al. (2012) similarly 
discuss this effector/regulatory balance in the lung in the context 
of asthma when compared to cancer. A paper by Mannie et al. 
(2012) describes how covalently coupling myelin derived peptide 
antigens to specific cytokines can target the antigen, presumably 
via the cytokine receptors, for presentation in a tolerogenic con-
text in rodent models as a potential treatment for inflammatory 
demyelinating diseases such as multiple sclerosis.
The final six articles discuss in more detail some of the barriers that 
remain to clinical translation of tolerogenic therapies to the clinic. 
Pasquet et al. (2011) question the long held assumption derived from 
classical neonatal tolerance that achieving hematopoietic chimerism 
is sufficient for full tolerance and provide evidence that Treg activity 
is also required. Costimulation blockade has long been recognized as 
a means to induce tolerance and Treg with negative or coinhibitory 
signaling thought to be important for the maintenance of anergy and 
Treg activity. McGrath and Najafian (2012) highlight the increasing 
complexity and redundancy of these multiple pathways and how this 
provides both challenges and potential opportunities in attempts to 
target them therapeutically. A particular barrier to the translation 
of traditional costimulation blockade is the presence of memory 
Being able to induce therapeutic tolerance for the treatment of 
immunological diseases was once considered by many to be an unat-
tainable dream, but recent developments in our understanding of 
immune regulation and tolerance-compatible immunosuppressive 
drugs may be turning that dream into reality. Tolerance induction in 
many rodent models of autoimmune disease and graft rejection is 
now almost trivial, and the problem has become not how to achieve 
tolerance experimentally but how to translate this knowledge to real 
clinical applications in human disease. This volume brings together 
17 articles that highlight some of the different approaches being 
investigated for translating potentially tolerogenic therapies to the 
clinic and the barriers that still need to be overcome.
The first two articles review the current status of clinical trials 
that result from large networks of basic laboratories and clinical 
consortia coordinated by the International Tolerance Network 
(Page et al., 2012) and the European Framework Program (Issa 
and Wood, 2012). These networks encompass an enormous range 
of trials including the minimization of immunosuppressive drugs 
in organ transplantation, the induction of mixed hematopoietic 
chimerism without myeloablation, and the use of a variety of anti-
body and cell therapies that attempt to elicit immune regulation in 
autoimmune disease, and they vary in scope from small pilot studies 
to large scale phase III clinical trials. In addition, patients who do 
achieve long term graft survival or remissions are being analyzed 
in order to try and determine potential signatures or biomark-
ers to indicate whether and when, during the course of therapy, 
immunological tolerance has been established.
The next three articles focus on attempts to exploit immune 
mechanisms, either by generating regulatory T cells (Treg) in vitro 
for subsequent direct administration to patients, or by utilizing 
the inherent ability of appropriately differentiated dendritic cells 
to present antigens for the induction of tolerance and Treg in 
vivo. Sagoo et al. (2012) discuss the issue of the antigen specific-
ity of Treg required for achieving full tolerance to alloantigens, 
particularly with respect to the issue of direct and indirect antigen 
presentation. The following two reviews focus on different aspects 
of tolerogenic antigen presenting cell-based therapies for the 
induction of immune regulation within the patient. Lutz (2012) 
focuses on the differentiation status of the dendritic cell required 
to present antigen for tolerance, Moreau et al. (2012) make a case 
for the use of autologous, donor antigen pulsed “TolDC.” Together, 
they highlight the promise of “cell therapy” in transplantation and 
autoimmunity.
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three papers discuss further, often ignored, potential difficulties for 
realizing tolerogenic therapies: the activation of the innate immune 
system, in particular NK cells (Benichou et al., 2012), the impact of 
lymphoid trafficking of regulatory and effector T cells to and from 
tissues (Burrell et al., 2011), and the interaction of the immune 
system with the tissue microenvironment, especially the vasculature 
(Bruneau et al., 2012).
In summary, we have made considerable progress toward trans-
lating potentially tolerogenic therapies from rodent models into the 
clinic, to the point where we now have a much clearer understand-
ing of the barriers that remain and how we may yet overcome them.
T cells, as discussed in the article by Krummey and Ford (2012). 
Tolerance in rodent models is often induced in mice where naïve T 
cells predominate, having been maintained in a low pathogen envi-
ronment while treatments for autoimmune disease are often tested 
at, or just after, disease induction. Real transplant and autoimmune 
patients, however, often have high frequencies of memory T cells 
generated either by heterologous immunity to previous pathogens 
or due to extended periods of autoreactive inflammatory disease. 
While memory T cells are often not dependent on CD154/CD40 
costimulation, the authors suggest that the addition of LFA-1 or 
VLA-4 blockade may be a way to overcome this barrier. The final 
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